Dexmethylphenidate for attention deficit hyperactivity disorder

Bibliography

• Faraone SV, Sergeant J, Gillberg C, Biederman J. Worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2(2):104-13
   PubMedGoogle Scholar
• Gadow KD, Nolan EE, Litcher L, Comparison of attention-deficit/hyperactivity disorder symptom subtypes in Ukrainian schoolchildren. J Am Acad Child Adolesc Psychiatry 2000;39:1520-7
   PubMed Web of Science ®Google Scholar
• Talaei A, Mokhber N, Abdollahian E, Attention deficit/hyperactivity disorder: a survey on prevalence rate among male subjects in elementary school (7 to 9 years old) in Iran. J Atten Disord 2009: published online 13 April 2009, doi:10.1177/1087054708329886
   Google Scholar
• Chan E, Zhan Z, Homer CJ. Health care use and costs for children with attention deficit hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch Ped Adolesc Med 2002;156:504-11
   PubMed Web of Science ®Google Scholar
• Jerome L, Segal A, Habinski L. What we know about ADHD and driving risk: a literature review, meta-analysis and critique. J Can Acad Child Adolesc Psychiatry 2006;15:105-25
   PubMed Web of Science ®Google Scholar
• Truls V. Impairment, diseases, and their relative risks of accident involvement: results from metaanalysis. Impaired Motorists, Methods of Roadside Testing and Assessment for Licensing (IMMORTAL). 2003 Deliverable R1.1. Available from: http://www.immortal.or.at/index.php [Last accessed 27 June 2009]
   Google Scholar
• Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006;36:159-65
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkley R, The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey replication. Am J Psychiatry 2006;163:716-23
   PubMed Web of Science ®Google Scholar
• Wax PM. Analeptic use in clinical toxicology: a historical appraisal. J Toxicol Clin Toxicol 1997;35:203-9
   PubMed Web of Science ®Google Scholar
• Davids E, Zhang K, Tarazi FL, Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacol 2002;160:92-8
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler GS, Wang G. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 2002;6(Suppl 1):S31-43
   PubMedGoogle Scholar
• Krause KH, Dresel SH, Krause J, Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000;285:107-10
   PubMed Web of Science ®Google Scholar
• Patrick KS, Caldwell RW, Ferris RM, Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 1987;241:152-8
   PubMed Web of Science ®Google Scholar
• Sun Z, Murry DJ, Sanghani SP, Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 2004;310:469-76
   PubMed Web of Science ®Google Scholar
• Modi N, Wang B, Noveck RJ, Gupta SK. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-released oral delivery system. J Clin Pharmacol 2000;40:1141-9
   PubMed Web of Science ®Google Scholar
• Davis E, Zhang K, Tarazi FI, Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology 2002;160:92-8
   PubMedGoogle Scholar
• Quinn D, Wigal S, Swanson J, Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43:1422-9
   PubMed Web of Science ®Google Scholar
• Wigal S, Swanson JM, Feifel D, A double-blind, placebo controlled trial of dexmethylphenidate hydrochloride and d, threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43:1406-14
   PubMed Web of Science ®Google Scholar
• Silva R, Muniz R, Pestrich L, Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006;16:239-51
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Adler LA, McGough JJ, Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007;61:1380-7
   PubMed Web of Science ®Google Scholar
• Adler LA, Spencer T, McGough J, Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord 2009;12:449-59
   PubMed Web of Science ®Google Scholar
• Wilens TE, Adler LA, Adams J, Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47:21-31
   PubMed Web of Science ®Google Scholar
• Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature Pediatrics 2003;111:179-85
   Google Scholar
• Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate: a review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 2002;22:1107-31
   PubMed Web of Science ®Google Scholar
• Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child 2005;90:801-6
   PubMed Web of Science ®Google Scholar
• Focalin. Manufacturer's Prescribing Information (2007). East Hanover, NJ: Novartis; 2007
   Google Scholar
• Quinn D, Greenhill LL, Silva RR, Cardiovascular safety of immediate-release and extended-release dexmethylphenidate in children with ADHD [abstract]. Presented at the 45th Annual Meeting of NCDEU, 6 – 9 June 2005, Boca Raton, FL, USA
   Google Scholar
• Psychiatric adverse events in attention deficit hyperactivity disorder (ADHD) clinical trials. FDA Pediatric Advisory Committee docket, 22 March 2006 Available from: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4210s_14_Mosholder_Psychiatric%20Adverse%20Events.ppt#321,16,Slide 16 [Last accessed 15 July 2009]
   Google Scholar
• Greenhill L, Muniz R, Ball R, Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention deficit/hyperactivity disorder. J Am Acad Child Adol Psychiatry 2006;45:817-23
   PubMed Web of Science ®Google Scholar
• The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-86
   PubMedGoogle Scholar
• Jensen PS, Hinshaw SP, Swanson JM, Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 2001;22:60-73
   PubMed Web of Science ®Google Scholar
• MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004;113:754-61
   PubMedGoogle Scholar
• Foltin R, Fischman M. Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 1991;28:3-48
   PubMed Web of Science ®Google Scholar